Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

ABSTRACT:

SUBMITTER: Kuzu O 

PROVIDER: S-EPMC12296657 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature